Drug intelligence / Profile preview

A-CAR028

Development stage: Phase 1
Lead developer: AbelZeta, Inc.
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

A-CAR028 is a chimeric antigen receptor T cell (CAR-T) therapy developed by AbelZeta Pharma. It is currently in preclinical development for the treatment of neoplasms (cancers). As a CAR-T cell therapy, A-CAR028 consists of genetically engineered T cells that express a synthetic receptor targeting specific antigens on tumor cells, enabling targeted immune-mediated destruction of cancerous cells. The precise target antigen and detailed mechanism have not been disclosed publicly.

Beyond the preview

Go deeper on A-CAR028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-CAR028.

Explore the full profile